{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-6532.0","upperLimit":"1002.0","value":"-21.0"}]}],"title":"Change from baseline @ Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-4084.0","upperLimit":"1085.0","value":"-1.00"}]}],"title":"Change from baseline @ Month 12"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"This shows the change in tumor volume from baseline to month 6 and from baseline to month 12 in patients treated with pasireotide LAR.","dispersionType":"Full Range","groups":[{"description":"All patients randomized regardless of pasireotide LAR dose.","id":"OG000","title":"Pasireotide LAR - All Participants"}],"paramType":"MEDIAN","populationDescription":"FAS: Comprises all patients to whom study treatment has been assigned by randomization. Protocol allowed to change treatment dose (eg, 20mg -\\> 40mg -\\>20mg -\\> 40mg -\\>60mg) based on efficacy and safety after 3month treatment. So we combined Arms/groups.","reportingStatus":"POSTED","timeFrame":"Baseline, Months 6 , 12","title":"Change of Tumor Volume From Baseline","type":"SECONDARY","unitOfMeasure":"mm^3"}